Parker Waichman LLP Files Lawsuits on behalf of Georgia and California Residents Alleging Development of Irreversible Eye Condition, NAION, after taking Ozempic

Parker Waichman filed two new lawsuits (Georgia Ozempic/NAION: Precup; California Ozempic/NAION: Grant) alleging permanent vision loss after taking Novo Nordisk’s semaglutide (Ozempic/Wegovy). The article cites a 2025 JAMA Ophthalmology review of nine cases and additional Harvard research suggesting substantially higher NAION risk (about 4x for diabetic users and 7x for non-diabetic weight-loss users). Overall, it frames Novo Nordisk as downplaying risk and allegedly failing to provide adequate warnings, which could increase legal and reputational risk for the company.

Analysis

This is not a first-order earnings event, but it is a slow-burn multiple problem for a stock that already trades as if its growth durability is close to unquestioned. The mechanism is simple: even if ultimate damages are immaterial, recurring litigation headlines can lift the discount rate applied to future obesity cash flows, especially when the market is paying for years of compound growth rather than this quarter’s results. The most important second-order effect is not a large settlement; it is incremental friction in physician adoption and patient persistence, which matters most in the non-diabetic weight-loss cohort where tolerance for adverse-event headlines is lowest.

The near-term catalyst path is about accumulation, not a single filing. If these claims remain isolated, the stock should shrug after a few sessions; if they consolidate into broader plaintiff activity, MDL momentum, or a label-warning discussion, the overhang can persist for 1-3 months and expand into 6-18 month valuation compression. Watch for any change in management’s legal reserve commentary, adverse-event disclosure language, or prescription growth deceleration in new-start metrics; those would be the first signals that the issue is affecting commercial momentum rather than just sentiment.

Contrarian view: the market may be overestimating legal liability and underestimating how hard it is to displace a category leader with entrenched prescriber behavior and strong reimbursement pull-through. That said, premium-multiple winners are punished more for uncertainty than for absolute dollars, so NVO can underperform even if the eventual legal bill is modest. HRGN looks like a non-factor here unless there is some undisclosed operational linkage to the claims stream or diagnostics ecosystem.

Key Decisions for Investors

• Tactically short NVO on any 2-3% headline-driven bounce; use a 1-3 month horizon and cover if there is no follow-through in prescription data or if management explicitly narrows the issue at the next earnings call.
• Relative-value pair: long LLY / short NVO for the next 4-8 weeks to express semaglutide-specific litigation risk versus the broader obesity franchise; thesis fails if the safety narrative broadens to the entire GLP-1 class.
• If options liquidity is adequate, buy a 2-4 month NVO put spread rather than outright puts to limit theta bleed; best entry is after an initial complacent rebound, not into the first headline selloff.
• No trade in HRGN absent a clearer exposure link; treat it as a watch item only.